Alter HJ, Holland PV, Purcell RH. The emerging pattern of post-transfusion hepatitis. Am J Med Sci. 1975;270(2):329–34.PubMedCrossRefGoogle Scholar
Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989;321(22):1494–500.PubMedCrossRefGoogle Scholar
Alter HJ. The road not taken or how I learned to love the liver: a personal perspective on hepatitis history. Hepatology. 2014;59(1):4–12. An interesting history regarding the difficulties in the identification and diagnosis of the Hepatitis C virus
Walsh JH, Purcell RH, Morrow AG, et al. Posttransfusion hepatitis after open-heart operations. Incidence after the administration of blood from commercial and volunteer donor populations. JAMA. 1970;211(2):261–5.PubMedCrossRefGoogle Scholar
Zaltron S, Spinetti A, Biasi L, et al. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12 Suppl 2:S2.PubMedCentralPubMedCrossRefGoogle Scholar
Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26(4):531–48.PubMedCrossRefGoogle Scholar
Strassburg CP, Manns MP. Liver transplantation: indications and results. Internist (Berl). 2009;50(5):550–60.CrossRefGoogle Scholar
Hsu SH, Yeh ML, Wang SN. New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol. 2013;2013:890517.PubMedCentralPubMedCrossRefGoogle Scholar
Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52(7):889–900.PubMedCrossRefGoogle Scholar
Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996;25(5):591–8.PubMedCrossRefGoogle Scholar
Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321(22):1501–6.PubMedCrossRefGoogle Scholar
Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352(9138):1426–32.PubMedCrossRefGoogle Scholar
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485–92.PubMedCrossRefGoogle Scholar
Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666–72.PubMedCrossRefGoogle Scholar
Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34(2):395–403.PubMedCrossRefGoogle Scholar
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.PubMedCrossRefGoogle Scholar
Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004;127(5):1347–55.PubMedCrossRefGoogle Scholar
Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.PubMedCentralPubMedCrossRefGoogle Scholar
Kwo P, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705–16.PubMedCrossRefGoogle Scholar
Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.PubMedCrossRefGoogle Scholar
Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839–50.PubMedCrossRefGoogle Scholar
Simeprevir (Olysio) for chronic hepatitis C. Med Lett Drugs Ther. 2014;56(1433):1–3.
Vaidya A, Perry CM. Simeprevir: first global approval. Drugs. 2013;73(18):2093–106.PubMedCrossRefGoogle Scholar
Traynor K. Sofosbuvir approved for chronic hepatitis C infection. Am J Health Syst Pharm. 2014;71(2):90.Google Scholar
Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;369(7):678–9.PubMedCrossRefGoogle Scholar
A Special Meeting Review Edition. Advances in the treatment of hepatitis C virus infection from EASL 2013. The 48th Annual Meeting of the European Association for the Study of the Liver, 24–28 April 2013, Amsterdam. Gastroenterol Hepatol (N.Y.). 2013(6 Suppl 3):1–18.
Witkop B. Paul Ehrlich and his magic bullets – revisited. Proc Am Philos Soc. 1999;143(4):540–57.PubMedGoogle Scholar
Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis. 2013;45 Suppl 5:S343–8.PubMedCrossRefGoogle Scholar
Kiser J, Burton J, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(10):596–606.PubMedCrossRefGoogle Scholar
Jacobson I, Dore G, Foster G. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naive patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). Washington, DC, 1–5 November 2013; Abstract 1122.
Lawitz E, Forns X, Zeuzem S. Simeprevir (TMC-435) peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in patients who relapsed after previous interferon based therapy: results from PROMISE, a phase III trial. Digestive Disease Week 2013; Abstract 869.
Zeuzem S, Berg T, Gane E. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon/ribavirin treatment: final SVR24 results of the ASPIRE trial. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver; 18–22 April 2012; Barcelona, Spain. Abstract 2.
Jacobson I, Ghalib R, Rodriguez-Torres M. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 1–5 November 2013; Washington, DC. Abstract LB-3. Initial results of an important study utilizing both FDA-approved oral therapies together, without ribavirin or pegylated-interferon. Additionally there were strong cure rates in traditionally difficult to treat patients.
American Association for the Study of Liver Diseases. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/initial-treatment-box-summary-recommendations-patients-who-are-initiating-therapy-hcv
. Accessed 13 May 2014. These are the joint recommendations of the AASLD and IDSA for the treatment of HCV, taking into account the current data on simeprevir and sofosbuvir. Note that these recommendations go even further than the FDA-approved indications for these two medications.
European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392–420.CrossRefGoogle Scholar
Hepatitis C Online. Simeprevir (Olysio). http://hepatitisc.uw.edu/page/treatment/drugs/simeprevir-drug
. Accessed 13 May 2014.
Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39(5):478–87.PubMedCrossRefGoogle Scholar
Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs. 2014;74(2):273–82.PubMedCrossRefGoogle Scholar
Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther. 2014;56(1434):5–6.
Lawitz E, Mangia A, Wyles D. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.PubMedCrossRefGoogle Scholar
Gane E, Lawitz E, Rodriguez-Torres M. Phase 3 randomized controlled trial of all-oral treatment with sofosbuvir+ribavirin for 12 weeks compared to 24 weeks of peg+ribavirin in treatment-naive GT2/3 HCV-infected patients (FISSION). Proceedings of the 48th Annual Meeting of the European Association for the Study of the Liver; 24–28 April 2013; Amsterdam. Abstract 5.
Jacobson I, Yoshida E, Sulkowski M. Treatment with sofosbuvir + ribavirin for 12 weeks achieves SVR12 of 78% in GT2/3 interferon-ineligible, -intolerant, or -unwilling patients: results of the phase 3 POSITRON trial. Proceedings of the 48th Annual Meeting of the European Association for the Study of the Liver; 24–28 April 2013; Amsterdam. Abstract 61.
Nelson D, Feld J, Kowdley K. All overall therapy with sofosbuvir + ribavirin for 12 or 16 weeks in treatment experienced GT2/3 HCV-infected patients: results of the phase 3 FUSION trial. Proceedings of the 48th Annual Meeting of the European Association for the Study of the Liver; 24–28 April 2013; Amsterdam. Abstract 6.
Zeuzem S, Dusheiko G, Salupere R. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 1–5 November 2013; Washington, DC. Abstract 1085.
Sulkowski M, Rodriguez-Torres M, Lalezari J. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 1–5 November 2013; Washington, DC. Abstract 212.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.PubMedCrossRefGoogle Scholar
Curry M, Forns X, Chung R. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 1–5 November 2013; Washington, DC. Abstract 213. Important study detailing the efficacy of this therapy administered before liver transplantation in achieving SVR-12 weeks after liver transplantation. Additionally, the study demonstrates important guidance on duration of therapy before liver transplantation and duration of viral negativity before liver transplantation to achieve this SVR.
Hepatitis C Online. Sofosbuvir (Sovaldi). http://hepatitisc.uw.edu/page/treatment/drugs/sofosbuvir-drug
. Accessed 13 May 2014.
Sulkowski M, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–21.PubMedCrossRefGoogle Scholar
Dore G, Lawitz E, Hezode C. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. Proceedings of the 48th Annual Meeting of the European Association for the Study of the Liver; 24–28 April 2013; Amsterdam. Abstract 1418.
Kowdley K, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222–32.PubMedCrossRefGoogle Scholar
Hepatitis C Online. Medications to treat HCV. http://hepatitisc.uw.edu/page/treatment/drugs
. Accessed 13 May 2014.
Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.PubMedCrossRefGoogle Scholar
Gilead. Gilead announces SVR12 rates from three phase 3 studies evaluating a once-daily fixed-dose combination of sofosbuvir ledipasvir for genotype 1 hepatitis C patients. Foster City, CA: Gilead Sciences. http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients. Accessed 13 May 2014. The ION trials were important in demonstrating high SVR rates in a diverse group of genotype 1 patients, including a treatment-experienced cohort. This trial also used a fixed-dose combination of sofosbuvir and daclatasvir, i.e. one pill – a significant achievement in design compared to prior therapies requiring a multitude of pills per day (and injections).
Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009;9(8):1707–13.PubMedCrossRefGoogle Scholar
Charlton M, et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 1–5 November 2013; Washington, DC. Abstract LB-2.
ClinicalTrials.gov. An expanded access phase 2 study of sofosbuvir with ribavirin and with or without pegylated interferon for 24 weeks in subjects who have undergone liver transplantation and who have aggressive, recurrent hepatitis C infection. http://clinicaltrials.gov/ct2/show/NCT01779518. Accessed 13 May 2014.
Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013;13(6):1601–5.PubMedCrossRefGoogle Scholar
Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther. 2010;32(11–12):1343–50.PubMedCrossRefGoogle Scholar
Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009;15(9):1063–71.PubMedCrossRefGoogle Scholar
Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 2012;18(12):1464–70.PubMedCrossRefGoogle Scholar
Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int. 2013;33 Suppl 1:56–62.PubMedCrossRefGoogle Scholar